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Abstract
Two useful strategies to speed up drug development are to increase the patient accrual rate
and use novel adaptive designs. Unfortunately, these two strategies often conflict when the
evaluation of the outcome cannot keep pace with the patient accrual rate and thus the interim
data cannot be observed in time to make adaptive decisions. A similar logistic difficulty arises
when the outcome is of late onset. Based on a novel formulation and approximation of the
likelihood of the observed data, we propose a general methodology for model-assisted designs
to handle toxicity data that are pending due to fast accrual or late-onset toxicity, and facilitate
seamless decision making in phase I dose-finding trials. The dose escalation/de-escalation rules
of the proposed time-to-event model-assisted designs can be tabulated before the trial begins,
which greatly simplifies trial conduct in practice compared to that under existing methods.
We show that the proposed designs have desirable finite and large-sample properties and yield
performance that is superior to that of more complicated model-based designs. We provide
user-friendly software for implementing the designs.
KEY WORDS: Adaptive design; dose finding; late-onset toxicity; maximum tolerated dose;
model-assisted designs.
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1 Introduction
Drug development enterprises are struggling because of unsustainably long development cycle
and high costs. The pharmaceutical industry and regulatory agencies both recognize the urgency
and necessity of speeding up drug development. Toward that goal, two common strategies are
to increase the accrual rate to shorten the trial duration (Dilts et al., 2008) and to use novel
adaptive designs for more efficient decision making (Kairalla et al., 2012). These two strategies,
unfortunately, often conflict. The majority of adaptive designs require that the endpoint is
quickly ascertainable, such that by the time interim decisions to be made, the outcomes of
patients already enrolled in the trial have been fully ascertained. When the accrual rate is
fast, some enrolled patients may not have completed their outcome assessment by the interim
decision making time, which causes a major logistic difficulty for implementing adaptive trial
designs. This is particularly true for phase I trials, where adaptive decisions of dose escalation
and de-escalation are mandated after each patient or patient cohort is treated. For example, in
a trial where the dose limiting toxicity (DLT) takes up to 28 days to evaluate and patients are
treated in cohorts of 3 patients, if the accrual rate is 2 patients per week, an average of 5 new
patients will be accrued while the investigators wait to evaluate the outcomes of the 3 previously
enrolled patients. The question is then: How can new patients receive timely treatment when
the previous patients’ outcomes are pending?
The same difficulty arises when the DLT is of late onset and requires a long assessment
window to be ascertained. For example, if the DLT assessment window of a new agent is 3
months, given the accrual rate of 3 patients per month, then an average of 6 new patients will
be accrued while investigators wait to evaluate the DLT outcomes of the 3 previously enrolled
patients. And still the investigators must determine how to provide the new patients with timely
treatment. The problem of late-onset toxicity is particularly common and important in the era
of targeted therapy and immunotherapy. A recent study reported that in 36 clinical trials of
molecularly targeted agents, more than half of the grade 3 or 4 toxicity events occurred after the
first treatment cycle (Postel-Vinay, 2011). Immunotoxicity is often of late onset, for instance,
endocrinopathies have been observed between post-treatment weeks 12 and 24 (Weber et al.,
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2015; June et al., 2017).
The fundamental issue associated with fast accrual and late-onset toxicity is that at the
interim decision time, some patients’ DLT data are pending (i.e., unknown), which causes diffi-
culty in making adaptive decisions. A number of novel phase I trial designs have been proposed
to accommodate pending data such that adaptive decisions can be made in real time. Cheung
and Chappell (2000) proposed the time-to-event continual reassessment method (TITE-CRM),
where the likelihood of each patient is weighted by his/her follow-up proportion. This weighted
likelihood approach has been applied to other designs such as the escalation with overdose control
method (Babb et al., 1998; Mauguen et al., 2011). Taking a different perspective, Yuan and Yin
(2011), Liu et al. (2013) and Jin et al. (2014) treated the pending DLT data as a missing data
problem, and proposed the expectation–maximization algorithm and Bayesian data augmenta-
tion method to facilitate real-time decision making. Lin and Yin (2017a) used the Kaplan–Meier
estimator to impute the missing toxicity data with the fractional DLT information. These
model-based designs yield excellent operating characteristics, but their use in practice has been
limited because they are often perceived by practitioners as difficult to understand, due to the
blackbox-style of decision making, and complicated to implement, because of the requirement of
repeated model fitting and estimation. Thus, in practice, the algorithm-based rolling six (R6)
design (Skolnik et al., 2008) is often used even though its performance is inferior to that of the
model-based designs (Zhao et al., 2011). To implement R6, investigators count the number of
patients with DLTs, the number of patients without DLTs and the number of patients with
pending outcomes, and then use the prespecified decision table to determine the dose for the
next new cohort, in a fashion similar to the 3+3 design.
The goal of this article is to develop new model-assisted phase I designs that can adaptively
handle pending DLT data due to fast accrual and/or late-onset toxicity. The proposed designs
are transparent and can be implemented in a simple way like the algorithm-based design (e.g.,
the R6 design), but they have desirable statistical properties and yield performance that is
comparable to that of the model-based designs (e.g., TITE-CRM). The proposed designs allow
users to tabulate the dose escalation and de-escalation rules before the trial begins. To conduct
the trial, there is no complicated model fitting and calculation, investigators only need to look
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up the decision table to make the dose-assignment decisions. Simulation studies show that albeit
simplistic, the proposed design yields excellent operating characteristics compared to those of
the more complicated model-based design.
Our approach is built upon the framework of model-assisted designs (Yan et al., 2017; Zhou
et al., 2018a), a novel class of designs that combine the simplicity of algorithm-based designs
with the superior performance of model-based designs. Model-assisted designs use a probability
model for efficient decision making like model-based designs, while their dose escalation and de-
escalation rules can be pre-tabulated before the onset of a trial, as with algorithm-based designs.
Ivanova et al. (2007) developed the cumulative cohort design based on the asymptotic distribution
of patient allocation of the up-and-down design using the Markov chain theory. Ji et al. (2010)
proposed the modified toxicity probability interval (mTPI) design that utilizes unit probability
mass (UPM) to guide the dose assignment. Liu and Yuan (2015) developed the Bayesian optimal
interval (BOIN) design that makes the decision of dose escalation and de-escalation by simply
comparing the observed toxicity rate at the current dose with two prespecified boundaries that
are optimized to minimize the incorrect decision of dose assignment. Yan et al. (2017) noted
the overdosing issue of the mTPI design due to the use of UPM and proposed the keyboard
design as a seamless improvement of the mTPI to achieve higher accuracy of identification of the
maximum tolerated dose (MTD) and better overdose control. The model-assisted designs have
been extended to drug-combination trials (Zhang and Yuan, 2016; Lin and Yin, 2017b; Pan et
al., 2018), to account for toxicity grades (Mu et al., 2018), and for phase I-II trials (Lin and Yin,
2017c). For overviews and comparison of model-assisted designs, see Zhou et al. (2018a) and
Zhou et al. (2018b). Because of their simplicity and good performance, model-assisted designs
have been increasingly used in practice. However, these designs cannot handle the issue of fast
accrual or late-onset toxicity, and they all require that accrued patients have completed DLT
assessment before treating the next patients.
Our study is motivated by a phase I trial planned at MD Anderson Cancer Center. The
objective is to find the MTD of a MEK inhibitor combined with 200mg pembrolizumab for
treating patients with advanced melanoma. Four doses, 100mg, 125mg, 150mg, and 175mg, of
the MEK inhibitor will be studied, administered orally twice daily on a schedule of 3 days on,
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4 days off. The maximum sample size is 21 patients, treated in cohort sizes of 3. As the DLT
of the treatment is expected to be of late onset, the clinical investigator set the DLT assessment
window at 3 months. The DLT will be scored using the NCI common Terminology Criteria for
Adverse Events, version 4.0. The accrual rate is expected to be 2 patients per month.
The remainder of this article is organized as follows. In Section 2, we formulate a new
likelihood-based approach to account for both observed and pending DLT data and develop
the TITE-keyboard design and study its theoretical properties. We also briefly discuss the
development of other model-assisted designs. As an illustration, we apply the TITE-keyboard
design to a phase I dose-finding trial in Section 3. In Section 4, we examine the performance
of the new design based on simulation studies and make extensive comparisons with existing
methods. Section 5 concludes with some remarks. The Supplementary Material contains the
proofs of theorems.
2 Methodology
Consider a phase I dose-finding trial with J prespecified doses and maximum sample size N . Let
pj denote the toxicity probability of dose level j, j = 1, . . . , J , with p1 < · · · < pJ , and φ denote
the target DLT rate. The objective is to find the MTD, defined as the dose that has the DLT
probability closest to φ. Patients are sequentially enrolled, and each patient is followed for a
fixed period of time, say τ , to assess the binary DLT outcome xi. If DLT is observed within the
assessment window (0, τ), xi = 1; otherwise, xi = 0. Let ti denote the time to DLT for patients
with xi = 1, where 0 ≤ ti ≤ τ . The DLT assessment window τ is prespecified by clinicians
such that it is expected to capture all DLTs relevant for the MTD determination. For many
chemotherapies, τ is often taken as the first cycle of 28 days; whereas for agents expected to
induce late-onset toxicity, e.g., some targeted or immunotherapy agents, τ can be several (e.g.,
3 to 6) months or longer.
2.1 Keyboard design
The proposed methodology to deal with fast accrual and late-onset toxicity is general and applies
to all model-assisted designs, including keyboard, mTPI as well as BOIN. For ease of exposition,
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we illustrate our approach using the keyboard design, reviewed briefly as follows. The keyboard
design starts by specifying a proper dosing interval I∗ = (φ−δ1, φ+δ2), referred to as the “target
key”, which represents the range of toxicity probabilities that are close enough to the target φ
so that they are regarded as acceptable in practice, where δ1 and δ2 are small constants, such
as δ1 = δ2 = 0.05. The keyboard design populates the interval toward both sides of the target
key, forming a series of keys of equal width that span the range of 0 to 1. For example, given
the target key of (0.25, 0.35), on its left side, we form 2 keys of width 0.1, i.e., (0.15, 0.25) and
(0.05, 0.15); and on its right side, we form 6 keys of width 0.1, i.e., (0.35, 0.45), . . . , (0.85, 0.95).
We denote the resulting intervals/keys as I1, . . . , IK , and assume that the k∗th interval is the
target key, i.e., Ik∗ = I∗.
Suppose that at a particular point during the trial, nj patients have been treated at dose
level j, and among them yj =
∑nj
i=1 xi patients experienced DLT. The keyboard design assumes
a beta-binomial model
yj |nj, pj ∼ Binom(nj, pj), (2.1)
pj ∼ Beta(1, 1) ≡ Unif(0, 1).
Given data Dj = (nj, yj) observed at dose level j, the posterior distribution arises as
pj |Dj ∼ Beta(yj + 1, nj − yj + 1), for j = 1, . . . , J. (2.2)
In contrast to model-based designs (e.g., the CRM), which model toxicity across doses using a
dose–toxicity curve model (e.g., a power or logistic model), the keyboard design models toxicity
at each dose independently, which simplifies the design and renders it possible to pre-tabulate the
decision rules of dose escalation and de-escalation. Modeling toxicity at each dose independently
is an essential feature of the model-assisted designs: mTPI assumes the same beta-binomial
model as above and BOIN only assumes the binomial model for yj.
To make the decisions of dose escalation and de-escalation, where j is the current dose level,
the keyboard design identifies the interval that has the largest posterior probability (referred to
as the “strongest” key), i.e.,
ks = arg max
k=1,··· ,K
{Pr(pj ∈ Ik |Dj)},
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which can easily be evaluated based on the posterior distribution of pj given by equation (2.2).
The keyboard design determines the next dose as follows: If ks < k
∗, escalate the dose to level
j+1; if ks = k
∗, retain the current dose level j; if ks > k∗, de-escalate the dose to level j−1. This
dose escalation/de-escalation process continues until the prespecified sample size N is exhausted,
and the MTD is selected as the dose for which the isotonic estimate (Barlow and Brunk, 1972)
of the toxicity rate is closest to the target φ.
The most appealing feature of the keyboard design is that its decision rule can be tabulated
before the trial begins, which greatly simplifies the practical implementation of the design. This
is possible because given the maximum sample size N , the possible outcome Dj = (nj, yj) is finite
for nj = 1, · · · , N and yj = 0, · · · , nj, and given each of the possible outcomes, the strongest key
and thus the dose escalation/de-escalation rule can be easily determined based on (2.2). This is
also the reason why the decision rules of the mTPI can be enumerated. We note that the mTPI2
(Guo et al., 2017), based on the concept of Ockham’s razor, ends up being the same design as
the keyboard design; thus, our approach described below is applicable to mTPI2 as well.
2.2 Likelihood with pending DLT data
When the accrual is fast or when there is late onset of DLT, the fundamental difficulty that
cripples the keyboard and other model-assisted designs is that by the time of decision making, say
time κ, the xi’s may not be observed for patients who have not completed their DLT assessment.
The data actually observed are indicator variables x˜i, i = 1, · · · , nj, which indicate that the
patient has experienced DLT (x˜i = 1) or not yet (x˜i = 0) by time κ. Clearly, x˜i = 1 implies
xi = 1, but when x˜i = 0, xi can equal 0 or 1.
Let δi indicate that the toxicity outcome xi has been ascertained (i.e., δi = 1) or is still
pending (i.e., δi = 0) by the decision time κ, and ui (ui ≤ τ) denote the actual follow-up time
for patient i up to that moment. For a patient with δi = 1, we have x˜i = xi, thus the likelihood
is given by
Pr(x˜i = xi|δi = 1) = pxij (1− pj)1−xi . (2.3)
For a patient with δi = 0, xi has not been ascertained yet and his/her DLT outcome is pending.
These patients with pending outcome data are a mixture of two subgroups: patients who will
7
not experience DLT (i.e., xi = 0), and patients who will experience DLT (i.e., xi = 1) but have
not experienced it yet by the interim decision time (i.e., ui < ti). Note that x˜i only takes a value
of 0 because once x˜i = 1 (i.e., the patient experiences DLT), xi becomes observable and δi = 1.
Therefore, for a patient with pending data with δi = 0, the likelihood is given by
Pr(x˜i = 0 | δi = 0) = Pr(xi = 0) Pr(x˜i = 0|xi = 0) + Pr(xi = 1) Pr(x˜i = 0 | xi = 1)
= Pr(xi = 0) + Pr(xi = 1) Pr(ti > ui | xi = 1)
= 1− pj + pj{1− Pr(ti ≤ ui | xi = 1)}
= 1− pjwi,
where wi = Pr(ti ≤ ui | xi = 1) can be interpreted as a weight, adjusting for the fact that the
DLT outcome has not been ascertained yet. We discuss how to specify wi later.
Given the observed interim data Doj = (x˜1, · · · , x˜nj , δ1, · · · , δnj) at the current dose level j,
the joint likelihood function is given by
L(pj | Doj ) ∝
nj∏
i=1
pδixij (1− pj)δi(1−xi)(1− wipj)1−δi
= p
y˜j
j (1− pj)mj
nj∏
i=1
(1− wipj)1−δi , (2.4)
where y˜j =
∑nj
i=1 δixi is the number of patients who experienced DLT by the interim time
κ, and mj =
∑nj
i=1 δi(1 − xi) is the number of patients who have completed the assessment
without experiencing DLT. Despite some similarity (e.g., using weights), our likelihood function
(2.4) differs from the one utilized in the TITE-CRM (Cheung and Chappell, 2000). In the
TITE-CRM, as long as the patient’s follow-up time ui < τ , that patient’s likelihood will be
weighted for a partial credit, no matter whether the patient has experienced DLT or not at that
moment. This is odd, however, because once a patient has experienced DLT, his/her toxicity
outcome xi has been ascertained. That patient’s data should receive full credit and the standard
binomial likelihood (2.3) should be used, even though the patient has not gone through the
whole assessment window yet. In contrast, our approach only weights the observations from the
patients whose xi is yet unknown, and for the patients whose xi has been ascertained, it uses
the standard binomial likelihood.
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Let pi(pj) denote the prior distribution for pj, e.g., pi(pj) = Beta(1, 1). The posterior distri-
bution f(pj | Doj ) is given by
f(pj | Doj ) ∝ pi(pj)L(pj | Doj ).
Although this posterior distribution can be routinely sampled by the Markov chain Monte Carlo
method and the strongest key thus can be identified to determine dose assignment, the issue
is that now it is impossible to enumerate the dose escalation and de-escalation rules before the
trial begins. This is because the posterior depends on individual-level continuous variable wi and
there is an infinite number of possible outcomes, prohibiting the enumeration of the decision rule.
As a result, the keyboard design with pending DLT data loses its most appealing advantage.
This issue also occurs for the other model-assisted designs.
To circumvent the aforementioned issue and maintain the simplicity of the keyboard design,
we approximate the last term in (2.4) as follows,
(1− wipj)1−δi ≈ (1− pj)wi(1−δi). (2.5)
When δi = 1, (1−wipj)0 = (1−pj)0 = 1; when δi = 0, we perform Taylor expansion of (1−pj)wi
at pj = 0, resulting in
(1− pj)wi = 1− wipj + wi(wi − 1)p2j + · · ·
Ignoring the second-order and higher terms, we obtain the approximation (2.5). Thus, the
likelihood (2.4) is approximated as
L(pj | Doj ) ∝ py˜jj (1− pj)m˜j , (2.6)
where
m˜j = mj +
nj∑
i=1
(1− δi)wi. (2.7)
This approximation is simple but powerful. It converts the non-regular likelihood (2.4) into a
binomial likelihood arising from “effective” binomial data D˜j = (n˜j, y˜j), where n˜j = y˜j + m˜j is
the “effective” sample size, and m˜j is the “effective” number of patients who have not experi-
enced DLT. As all model-assisted designs are based on the binomial likelihood, this means that
9
these designs can be seamlessly extended to accommodate pending DLT data using the approx-
imated likelihood (2.6), as demonstrated in Section 2.4. In addition, because the approximated
likelihood (2.6) depends on the aggregated value of the wi’s, rather than the individual value of
wi, the approximation renders it possible to enumerate the decision rules for the resulting de-
sign, maintaining the most important feature of the model-assisted designs. Lastly, the following
theorem indicates that (2.6) provides a very accurate approximation of the true likelihood (2.4).
Theorem 1. Let l(wi, δi, pj) = (1 − wipj)1−δi and l˜(wi, δi, pj) = (1 − pj)wi(1−δi). The approxi-
mation error is bounded by
d(wi, δi, pj) = |l(wi, δi, pj)− l˜(wi, δi, pj)| ≤ (1− βjpj)− (1− pj)βj ,
where βj = log{−pj/ log(1− pj)}/ log(1− pj). Specifically, for any pj ≤ 0.4, the approximation
error d(wi, δi, pj) < 0.0255.
The proof of Theorem 1 is provided in the Supplementary Material. To illustrate the accuracy
of the approximation, we consider two examples: (a) nj = 5 patients have been treated and only
mj = 2 patients have finished the assessment without any DLT, and the weights wi for the
remaining 3 patients are 0.3, 0.4, and 0.5, respectively; (b) nj = 12 patients have been treated,
yj = 1 DLT has been observed, mj = 4 patients have finished the assessment without any DLT,
and the weights wi for the remaining 7 patients are 0.1, 0.2, . . . , 0.7, respectively. Given the prior
pj ∼ Unif(0, 1), Figure 1 shows the true and approximated posterior distribution functions,
indicating that the approximation is very accurate.
2.3 Specifying the weight
We consider three different schemes for specifying the weight wi that appears in the approximated
likelihood (2.6).
(1) Uniform weight
Following the TITE-CRM, the simplest way is to assume that the time-to-toxicity outcome is
uniformly distributed over the assessment period (0, τ), i.e., ti | xi = 1 ∼ Unif(0, τ), leading to
wui = Pr(ti < ui | xi = 1) = ui/τ. (2.8)
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As a result, wui can be interpreted as the follow-up proportion that patient i has finished. As
shown later in simulation, although the uniform scheme seems very restrictive, it yields re-
markably robust performance. This was also observed by Cheung and Chappell (2000) in the
TITE-CRM, and based on that they recommended the uniform weight as the default for general
use.
(2) Piecewise uniform weight
A more flexible weighting scheme is to assume that the time to toxicity follows a piecewise uniform
distribution, which partitions (0, τ) into several intervals and assumes a uniform distribution
within each interval. By increasing the number of partitions, the piecewise uniform distribution
can approximate any shape of the time-to-toxicity distribution. This makes it particularly useful
to incorporate prior information on the time to toxicity, ti. For ease of exposition, we consider
three partitions that are often adequate for practical use. We partition the assessment window
(0, τ) into the initial part (0, τ/3), the middle part (τ/3, 2τ/3) and the final part (2τ/3, τ), and
assume that ti is uniformly distributed in each interval. Let (υ1, υ2, υ3) be the prior probability
that the DLT would occur at the three parts of the assessment window, where υ1 + υ2 + υ3 = 1.
For example, prior data may suggest that the DLT is more likely to occur late in the assessment
window, in which case we can choose υ3 > υ2 > υ1. It then follows that
wpi = Pr(ti < ui | xi = 1) =

3υ1ui/τ, ui ∈ (0, τ/3),
υ1 − υ2 + 3υ2ui/τ, ui ∈ (τ/3, 2τ/3)
υ1 + υ2 − 2υ3 + 3υ3ui/τ, ui ∈ (2τ/3, τ),
,
where wpi can be interpreted as the weighted follow-up probability that patient i has completed
the assessment time.
(3) Adaptive weight
The first two schemes determine wi based on prespecified prior distributions. The adaptive
scheme estimates wi adaptively during the trial based on the accumulating interim data. Note
that ti is the time to DLT for patients who have experienced DLT (i.e., xi = 1), thus its support
is (0, τ). Hence, we assume that ti follows a scaled Beta distribution
ti | xi = 1, λ, γ ∼ τ × Beta(λ, γ);
λ, γ ∼ pi(λ, γ),
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where pi(λ, γ) is the prior distribution of the unknown parameters λ and γ, e.g., independent
gamma prior, Gamma(0.1, 0.1). As data are very sparse in phase I trials, to borrow information,
we consider that given xi = 1, ti follows the same distribution across doses. Letting D = ∪Jj=1Dj,
the posterior estimate of wi is given by
wai =
∫ ∞
0
∫ ∞
0
∫ ui
0
g(ti | λ, γ)f(λ, γ | D)dtidλdγ,
where f(λ, γ | D) is the posterior distribution of λ and γ, and g(ti | λ, γ) is the density of ti based
on the scaled Beta distribution. Because the adaptive schemes allows wi to adaptively change
with the observed interim data, it is more flexible and theoretically more favorable. However, the
numerical study (in Section 4)shows that the adaptive scheme provides minimal improvement
over the first two schemes, but is substantially more complicated, largely because the data are
too sparse to provide reliable estimates of the time to DLT. Thus, we recommend the first two
weighting schemes for general use.
2.4 TITE-keyboard design
Application of the proposed methodology to the keyboard design is straightforward. We refer to
the resulting design as the TITE-keyboard design. The decision rule of the TITE-keyboard design
is almost the same as that of the keyboard design. The only change is that to make decisions
of dose escalation and de-escalation, we replace the complete data Dj = (nj, yj), which are not
observable when some DLT data are pending, with the “effective” binomial data D˜j = (n˜j, y˜j) for
calculating the posterior distribution of pj and identifying the strongest key. Once the strongest
key is identified, the same dose escalation/de-escalation rule is used to guide the dose transition.
Compared to the model-based TITE-CRM, the most appealing feature of TITE-keyboard is
that its dose transition rule can be tabulated before the trial begins; see Table 1 as the decision
table with the target DLT rate φ = 0.3. To conduct the trial, there is no need for real-time
model fitting, investigators only need to count the number of patients with DLTs (i.e., y˜j), the
number of patients with data pending (i.e., c˜j =
∑nj
i=1(1−δi)), the “effective” number of patients
without DLT (i.e., m˜j), and then use the decision table to determine the dose assignment for the
next new cohort. Another feature of the TITE-keyboard design is that its decision table does not
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depend on the weighting scheme or the length of the DLT assessment window. Table 1 applies
no matter which of the aforementioned three weighting schemes is used and no matter the length
of the assessment window. This is because the likelihood (2.6) only depends on m˜j, which is the
“effective” number of patients without DLT. Moreover, when all the pending DLT data become
available, i.e., D˜j = Dj, the TITE-keyboard design reduces to the standard keyboard design in
a seamless way.
For patient safety, we require that dose escalation is not allowed until at least 2 patients have
completed the DLT assessment at the current dose level. In addition, we impose an overdose
control/stopping rule: at any time during the trial, if any dose j′ satisfies Pr(pj′ > φ | nj′ , y˜j′) > η,
then that dose and any higher doses are regarded as overly toxic and should be eliminated from
the trial, and the dose is de-escalated to level j′ − 1 for the next patients, where η is the
prespecified elimination cutoff, say η = 0.95. If the lowest dose level is eliminated, the trial
should be early terminated. Table 1 also reflects such safety and overdose control rules.
When dealing with fast accrual or late-onset toxicities, the top concern is patient safety as the
patients with pending outcome data who have not experienced DLT at the interim decision time
may yet experience DLT late in the follow-up period. Any reasonable design that handles late-
onset toxicity should take that fact into account in its decision making, which can be described
by the monotonicity property. Let Dsj denote the “cross-sectional” interim data obtained by
setting xi = x˜i, i.e., treating the patients’ temporary DLT outcomes at the interim time as their
final DLT outcomes at the end of the assessment window. In other words, Dsj = (nj, y˜j). Let
a(Dj) = −1, 0 and 1 respectively denote the decisions of dose de-escalation, retaining the current
dose and dose escalation based on the data Dj.
Definition (Monotonicity) A dose-finding design is monotonic if a(Doj ) ≤ a(Dsj) for j =
1, . . . , J .
Monotonicity indicates that the decision of dose transition based on the observed data Doj
should be less aggressive than that based on Dsj . This is a property that any reasonable design
should obey to reflect that patients who have not experienced DLT by the interim decision time
may yet experience DLT late in the follow-up period. As shown in the Supplementary Material,
the TITE-keyboard design has this property.
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Theorem 2. The TITE-keyboard design is monotonic.
Another finite-sample design property of practical importance is coherence. Cheung (2005)
originally defined coherence as a design property by which dose escalation (or de-escalation) is
prohibited when the most recently treated patient experiences (or does not experience) toxicity.
Liu and Yuan (2015) extended that concept and defined two different types of coherence: short-
memory coherence and long-memory coherence. They referred to the coherence proposed by
Cheung (2005) as short-memory coherence because it concerns the observation from only the
most recently treated patient, ignoring the observations from the patients who were previously
treated. Long-memory coherence is defined as a design property by which dose escalation (or
de-escalation) is prohibited when the observed toxicity rate among all accumulative patients
treated at the current dose is larger (or smaller) than the target toxicity rate. From a practical
viewpoint, long-memory coherence is more relevant because when clinicians determine whether
a dose assignment is practically plausible, they almost always base their decision on the toxicity
data that have accumulated from all patients, rather than only the single patient most recently
treated at that dose. In practice, patients in phase I trials are very heterogeneous, therefore, the
toxicity outcome from a single patient can be spurious. For example, suppose the target DLT
rate φ = 0.3 and at the current dose, the most recently treated patient experienced DLT but
none of the 7 patients previously treated at the same dose had DLT. As the overall observed DLT
rate at the current dose is 1/8, escalating the dose should not be regarded as an inappropriate
action, although it violates short-memory coherence. It can be shown that the keyboard design
is long-memory coherent. The proof of Theorem 3 is given in the Supplementary Material.
Theorem 3. The TITE-keyboard design is long-memory coherent in the sense that the probability
of escalating (or de-escalating) the dose if the estimated toxicity rate p˜j = y˜j/n˜j at the current
dose is greater (or less) than the target toxicity rate, that is, Pr(Escalation | p˜j > φ,Doj ) = 0,
and Pr(De-escalation | p˜j < φ,Doj ) = 0.
In addition to monotonicity and coherence, the TITE-keyboard design also possesses a desir-
able large-sample convergence property. The proof is provided in the Supplementary Material.
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Theorem 4. Given a finite assessment window, as the number of treated patients goes to infinity,
the dose assignment of the TITE-keyboard design converges almost surely to the dose level j with
pj ∈ (φ− δ1, φ+ δ2).
2.5 Extension to mTPI and BOIN designs
The proposed methodology can be directly applied to mTPI, another model-assisted design. The
mTPI design specifies three dosing intervals: the proper dosing interval I0 = (φ − δ1, φ + δ2),
underdosing interval I1 = (0, φ − δ1) and overdosing interval I−1 = (φ + δ2, 1). The dose
escalation/de-escalation decision is based on the UPM of the three intervals:
UPMk(Dj) =
Pr(pj ∈ Ik|Dj)
length of Ik =
∫
Ik f(pj | Dj)dpj∫
Ik 1dpj
, k = −1, 0, 1. (2.9)
The mTPI design assumes the same beta-binomial model (2.1) and calculates the UPMk’s based
on the posterior of pj given by (2.2). The dose-assignment decision of mTPI is then a(Dj) =
arg max
k={−1,0,1}
UMPk(Dj); that is, making the decision that corresponds to the largest UPM.
To apply the proposed methodology, the only change needed is to replace the complete data
Dj, potentially unobserved due to late-onset toxicity or fast accrual, by the “effective” data D˜j
in (2.9) when calculating the UPMs. Once the UPMs are determined, the decision rules remain
the same. We refer to the resulting design as the TITE-mTPI. Table S1 in the Supplementary
Material shows the dose escalation/de-escalation rule for the TITE-mTPI design.
Last, we briefly discuss how to apply our methodology to the BOIN design. The BOIN
design has a simpler and more transparent decision rule than the mTPI and keyboard designs.
It does not require calculating the posterior distribution of pj and enumerating all possible
outcomes for (nj, yj). BOIN makes the decision of dose escalation/de-escalation by comparing
the observed DLT rate pˆj = yj/nj with a pair of dose escalation and de-escalation boundaries
(λe, λd) that are optimized to minimize the probability of incorrect dose-assignment decisions,
assuming yj ∼ Binom(nj, pj). If pˆj ≤ λe, escalate the dose; if pˆj ≥ λd, de-escalate the dose;
otherwise, i.e., λe < pˆj < λd, stay at the same dose. Liu and Yuan (2015) provided a closed-
form formula for (λe, λd), and showed that the dose escalation/de-escalation rule of the BOIN is
equivalent to using the frequentist likelihood ratio test statistic, or Bayesian factor, to guide the
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dose transition. That is, BOIN has both frequentist and Bayesian interpretations.
In the presence of pending DLT data due to fast accrual or late-onset toxicity, BOIN cannot
be used because pˆj is not available as yj is unknown. To address this issue, utilizing our ap-
proximation with the “effective” binomial data (n˜j, y˜j), we can simply use p˜j = y˜j/n˜j to replace
pˆj as the maximum likelihood estimate of pj, and then make the decision of dose escalation/de-
escalation in the same way as in the original BOIN. Due to space limitation, the operating
characteristics and theoretical properties of this approach are not studied here.
2.6 Software
To facilitate the use of the TITE-keyboard and TITE-mTPI designs, we have developed graphical
user interface-based software that allows users to generate the dose-assignment decision table,
conduct simulations, obtain the operating characteristics of the design, and generate a trial
design template for protocol preparation. The software will be freely available at http://www.
trialdesign.org.
3 Trial illustration
We apply the proposed TITE-keyboard design to the melanoma trial described in the Introduc-
tion. The target toxicity probability φ = 0.3, assessment window τ = 3 months, and patients are
enrolled at the rate of 2 patients per month. The maximum sample size is 21 patients. Patients
are treated in cohorts of 3, starting from the lowest dose level.
Given the target toxicity rate of 0.3, Table 1 shows the TITE-keyboard decision rule with a
cohort size of 3. Figure 2 displays the whole trial procedure using the TITE-keyboard design
and the uniform scheme wui . Patients in the first cohort were treated at the lowest dose level.
Since no DLT was observed and the TITE-keyboard design requires at least two finished patients
before dose escalation, the trial was suspended until day 120 when the first two patients had
completed the assessment. Following the TITE-keyboard decision rule, the second cohort was
treated at dose level 2. On the arrival of the third cohort (day 165), one DLT had occurred
on day 145 among the second cohort, and the follow-up proportions for patients 5 and 6 were
1/3 and 1/6, respectively, leading to m˜j = 0.5. According to Table 1, dose de-escalation was
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needed. Had we treated the two pending outcomes as non-DLTs, the keyboard design based
on (nj, yj) = (3, 1) would have recommended retaining the current dose for the next cohort of
patients. However, since the two patients with pending outcome data had been followed for only
a short period, there was greater uncertainty regarding the toxicity probabilities of dose level 2
and it was preferable to be conservative. The TITE-keyboard automatically took into account
such uncertainty and de-escalated the dose to the first level for treating the third cohort. When
patient 10 arrived, no DLT was observed among the 6 patients at that dose level, thus the forth
cohort received dose level 2. On day 255, 6 patients had been treated at level 2, with 3 finished
patients. The observed data at level 2 were (nj, yj, cj, m˜j) = (6, 1, 3, 3), which were less than the
dose-escalation boundary. As a result, the fifth cohort was still treated at dose level 2. On day
300, the observed data at that level were updated to be (nj, yj, cj, m˜j) = (9, 1, 5, 5.5), and the
dose for patients 15 to 18 was escalated to level 3. As one DLT was observed at level 3 before
the arrival of patient 19, patients in the last cohort were assigned to dose level 2. Based on
TITE-keyboard, the total trial duration was 14 months. In contrast, the trial would have run
about 31.5 months if we had applied standard adaptive designs that require full DLT assessment
before enrolling each new cohort. At the end of the trial, a total of 12 patients had been treated
at dose level 2, and 3 DLTs were observed. The estimated toxicity rate at dose level 2 was 0.25,
thus it was selected as the MTD.
To assess the accuracy of the approximated likelihood function (2.6), we provide the decisions
by the TITE-keyboard design respectively with the true likelihood (2.4) and the approximated
likelihood (2.6) in Table S2 in the Supplementary Material. As expected, the posterior model
probabilities calculated based on the true and approximated likelihoods are almost identical,
thus, the decisions made based on the approximated likelihood are consistent with those based
on the true likelihood.
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4 Numerical studies
4.1 Fixed scenarios
We perform simulation studies to examine the operating characteristics of the proposed TITE-
keyboard and TITE-mTPI designs. We consider six dose levels, with the target toxicity proba-
bility φ = 0.30. The toxicity assessment window is τ = 3 months. A maximum of 36 patients
will be recruited in cohorts of 3, with the accrual rate of 2 patients per month. Six toxicity
scenarios with different locations of the MTD and various shapes of dose–toxicity curves are
considered; see Table 2. The time-to-toxicity outcomes are simulated from Weibull distributions
by controlling that 50% of the toxicity events occur in the latter half of the assessment window
(τ/2, τ) (Liu et al., 2013). Under each scenario, we compare the proposed TITE-keyboard and
TITE-mTPI designs with the R6 design, TITE-CRM, and the standard CRM based on 10,000
simulated trials. The uniform weighting scheme is adopted for the TITE-CRM, TITE-keyboard
and TITE-mTPI designs. For TITE-CRM and CRM, the power model is utilized, where the
skeleton is chosen based on the method of Lee and Cheung (2009), with the initial MTD guess
being dose level 3 and the half-width of the indifference interval being 0.06. The (standard)
CRM cannot directly handle late-onset toxicity. To implement the CRM, we suspend accrual
after treating each cohort of patients until all pending data are fully observed before enrolling
the next cohort of patients. The CRM serves as the benchmark to assess the performance of
the other designs. For fair comparison, in the TITE-keyboard, TITE-mTPI and TITE-CRM
designs, we apply the same safety rule that dose escalation is not allowed until two patients at
the current dose level have finished the DLT assessment. When the R6 design stops the trial
early (e.g., when 2 DLTs are observed among 2 patients) before the exhaustion of 36 patients,
the remaining patients are treated at the selected “MTD” as the cohort expansion, such that
the sample sizes of the five designs are matched.
Table 2 summarizes the simulation results, including the dose selection percentage; the per-
centage of patients treated at each dose; the average trial duration; the early stopping percentage;
the risk of poor allocation, defined as the percentage of simulated trials allocating fewer than 6
patients to the MTD; and the risk of overdosing, defined as the percentage of simulated trials
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that treat more than half of the patients at doses above the MTD. In terms of MTD selection and
patient allocation, the TITE-CRM, TITE-mTPI and TITE-keyboard designs yield performances
generally comparable to those of the CRM, while the R6 design performs the worst as it inherits
the drawbacks of the 3+3 design. Compared to the CRM, the TITE-CRM, TITE-mTPI and
TITE-keyboard designs dramatically shorten the trial duration by approximately 22 months. In
scenarios 1 and 2, TITE-CRM requires a slightly shorter trial duration than TITE-keyboard
because it is more likely to stop the trial early. R6 requires repeated suspension of accrual until
6 patients have been treated at the current dose level. As a result, it generally has a longer trial
duration than the other three time-to-event methods.
When dealing with late-onset toxicities, it is not desirable to be overly conservative and retain
low doses too long because that allocates too many patients to subtherapeutic doses. This early-
settlement problem is quantified by the risk of poor allocation. Among the considered designs,
the TITE-keyboard and TITE-CRM have the lowest risk of poor allocation, indicating that these
two designs can quickly recover from the false settlement and allocate patients to the appropriate
doses. TITE-mTPI is more likely to become stuck at incorrect doses than TITE-keyboard and
TITE-CRM, with a higher risk of poor allocation. The R6 design performs the worst since it
is excessively conservative and would not escalate the dose until 6 patients have been treated
at the current dose level. When handling late-onset toxicities, it is also not desirable to be
overly aggressive and treat a large percentage of patients at overly toxic doses. We measure this
design behavior using the risk of overdosing. According to Table 2, the TITE-keyboard design is
safer than the TITE-CRM and TITE-mTPI designs, demonstrating the lowest risk of overdosing
patients among the three designs.
To investigate the accuracy of our proposed approximation procedure, we implement the
TITE-keyboardt design that is based on the true likelihood function (2.4), where the superscript
“t” represents the true likelihood. As shown in Table 2, the operating characteristics of the
TITE-keyboard design are essentially identical to those of the TITE-keyboardt design. To gain
more insight, we record the percentage of discrepancy in dose assignment between the two designs
across 10,000 simulated trials, which is merely about 1.3% on average for the considered scenarios.
These results verify the high accuracy of the approximated likelihood function.
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4.2 Sensitivity analysis on different calculation schemes of wi
To assess the robustness of TITE-keyboard to different weighting schemes for wi, we com-
pare the performance of TITE-keyboard based on the uniform scheme with those based on
the piecewise uniform and adaptive schemes. For the piecewise uniform scheme, we choose
(υ1, υ2, υ3) = (1/6, 2/6, 3/6) so that the prior information indicates that half of the toxicities may
occur in the final part of the assessment window. For the adaptive scheme, we take independent
Gamma(0.5, 0.5) prior distributions for λ and γ. We respectively refer to the TITE-keyboard
designs based on these three calculation schemes as TITE-keyboardu, TITE-keyboardp, and
TITE-keyboarda, and compare their percentages of correct selections and percentages of correct
allocations in Figure 3. The performance of TITE-keyboarda is almost the same as that of
TITE-keyboardu. There are some very slight differences between the operating characteristics of
TITE-keyboardp and TITE-keyboardu. When more late-onset prior information (i.e., the piece-
wise uniform scheme) is incorporated, the TITE-keyboardp design tends to be more conservative
compared to that using the uniform scheme: if the MTD lies in the lower dose region (scenar-
ios 1 and 2), the performance of TITE-keyboardp is better than that of TITE-keyboardu; and
vice versa, TITE-keyboardu outperforms TITE-keyboardp in scenarios 5 and 6, where high dose
levels are the MTD. Nonetheless, the differences between the operating characteristics of TITE-
keyboardp and TITE-keyboardu are very minor across the six considered scenarios, showing that
the TITE-keyboard design is not sensitive to the weighting schemes of wi.
4.3 Random scenarios
To ensure that the simulation results represent the general performance of the designs, we con-
ducted a large-scale simulation study to compare the proposed TITE-keyboard, TITE-mTPI
designs with R6 and TITE-CRM based on randomly generated dose–toxicity scenarios. We con-
sidered 12 configurations that cover various target toxicity rates, numbers of cohorts, cohort sizes,
distributions of time-to-toxicity outcomes, percentages of toxicity occurring in the latter half of
the assessment window (τ/2, τ), and accrual rates. Details of the configurations are provided
in Table S3 in the Supplementary Material. Under each configuration, we randomly generated
50,000 random dose–toxicity scenarios based on the procedure described in Zhou et al. (2018a).
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The setup of the comparative designs is the same as that described in Section 4.1.
Figure 4 shows the simulation results, which are generally consistent with those obtained in
the fixed scenarios. TITE-keyboard, TITE-mTPI and TITE-CRM have similar accuracy when
identifying the MTD, and they uniformly outperform the R6 design. TITE-keyboard is safer and
easier to implement than TITE-CRM. Between the two model-assisted designs, TITE-keyboard
has substantially lower risk of overdosing patients and having poor allocation than TITE-mTPI
and thus is preferable for practical use. By comparing the operating characteristics of TITE-
keyboard across the 12 simulation configurations, we additionally found that the performance of
TITE-keyboard is robust to the late-onset toxicity profile, including the ratio of the assessment
window and the patient inter-arrival time as well as the distribution of time-to-toxicity outcomes.
5 Concluding remarks
We have proposed general methodology to allow model-assisted trial designs to handle late-
onset toxicity and fast accrual. We have formulated a new likelihood-based approach to account
for pending DLT data and have derived a novel approximation of the observed likelihood that
enables all existing model-assisted designs to accommodate pending data in a seamless way
without destroying their simplicity. In particular, we have proposed the TITE-keyboard design,
which has been demonstrated to possess desirable finite-sample and large-sample properties:
monotonicity, coherence and consistency. The TITE-keyboard design is simple and easy to
implement, yet has superior performance that is comparable to that of the more complicated
TITE-CRM design.
Conducting clinical trials is a complicated, multidisciplinary effort, involving clinicians, a
medical support team and statisticians. When determining a trial design to use in practice,
transparency and simplicity are viewed as important as statistical properties. The proposed
designs allow users to tabulate the dose escalation and de-escalation rules before the trial begins.
To conduct the trial, there is no complicated model fitting and calculation, the investigators
only need to look up the decision table to make the decision of dose escalation and de-escalation,
which greatly simplifies the implementation of the design. Importantly, such simplicity does not
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sacrifice performance. Thus, the proposed TITE-keyboard design has great potential for being
adopted by practitioners to accelerate drug development.
To be conservative, we adopt an ad hoc rule to prohibit dose escalation and suspend patient
accrual if fewer than two patients at the current dose level have been completely followed. As
another approach, we can only allow for dose escalation if Pr(pj < φ | nj, y˜j) is greater than some
prespecified threshold. However, due to the small sample size and the nature of the binomial
likelihood, these two rules tend to produce similar operating characteristics.
6 Supplementary Materials
This supplementary material consists of the proofs of Theorems 1–4 and other technical details
given in the paper.
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Figure 1: The true and approximated posterior functions based on the observed data: (a) nj = 5
patients have been treated and only mj = 2 patients have finished the assessment without any
DLT, and the weights for the remaining 3 patients are 0.3, 0.4, and 0.5; (b) nj = 12 patients
have been treated, y˜j = 1 DLT has been observed, mj = 4 patients have finished the assessment
without any DLT, and the weights for the remaining 7 patients are 0.1, 0.2, . . . , 0.7. The prior
distribution of pj is pj ∼ Unif(0, 1); y˜j and m˜j respectively represent the “effective” numbers of
patients with DLT and patients without DLT by the interim time γ; Ik∗ represents the target
key.
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Figure 2: Hypothetical phase I clinical trial using the TITE-Keyboard design. The target toxicity
rate is 0.3, and the toxicity assessment window is 3 months. Patients are treated in cohort sizes
of 3, and the accrual rate is one patient every 15 days. The number above the “x” indicates the
time when DLT occurs.
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Figure 3: Sensitivity analysis of different schemes for the weight wi = Pr(ti < ui | xi = 1)
based on the six fixed scenarios in Table 2. Three different schemes are considered. Uniform:
ti | xi = 1 ∼ Unif(0, τ); Piecewise uniform: ti | xi = 1 ∼ υ1Unif(0, τ/3) + υ2Unif(τ/3, 2τ/3) +
υ3Unif(2τ/3, τ); Adaptive: wi is adaptively estimated based on the observed data and the prior
ti | xi = 1 ∼ τ × Beta(λ, γ), λ, γ ∼ Gamma(0.5, 0.5).
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Figure 4: Simulation results based on 50000 randomly generated scenarios. The target toxicity
probability in scenarios 1–6 is 0.2, while that in scenarios 7–12 is 0.3.
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Table 1: Dose escalation and de-escalation boundaries for TITE-keyboard with a target DLT
rate of 0.3 and cohort size of 3, up to 12 patients.
nj y˜j c˜j Escalation Stay De-escalation
3 0 ≤ 1 Y
3 0 ≥ 2 Suspend accrual
3 1 0 Y
3 1 1 ≤ c˜j ≤ 2 m˜j > 1.88 m˜j ≤ 1.88
3 2 ≤ 1 Y
3 3 0 Y&Eliminate
6 0 ≤ 6 Y
6 1 ≤ 1 Y
6 1 2 ≤ c˜j ≤ 3 m˜j ≥ 3.07 m˜j < 3.07
6 1 4 ≤ c˜j ≤ 5 m˜j ≥ 3.07 1.88 < m˜j > 3.07 m˜j ≤ 1.88
6 2 0 Y
6 2 1 ≤ c˜j ≤ 4 m˜j > 3.75 m˜j ≤ 3.75
6 3 ≤ 3 Y
6 4 ≤ 2 Y&Eliminate
9 0 ≤ 9 Y
9 1 ≤ 4 Y
9 1 5 ≤ c˜j ≤ 6 m˜j ≥ 3.07 m˜j < 3.07
9 1 7 ≤ c˜j ≤ 8 m˜j ≤ 3.07 1.88 < m˜j < 3.08 m˜j ≤ 1.88
9 2 0 Y
9 2 1 ≤ c˜j ≤ 3 m˜j ≥ 6.15 m˜j < 6.15
9 2 4 ≤ c˜j ≤ 7 m˜j ≥ 6.15 3.75 < m˜j < 6.15 m˜j ≤ 3.75
9 3 0 Y
9 3 1 ≤ c˜j ≤ 6 m˜j > 5.63 m˜j ≤ 5.63
9 4 ≤ 5 Y
9 5 ≤ 4 Y&Eliminate
12 0 ≤ 12 Y
12 1 ≤ 7 Y
12 1 8 ≤ c˜j ≤ 9 m˜j ≥ 3.07 m˜j < 3.07
12 1 10 ≤ c˜j ≤ 11 m˜j ≥ 3.07 1.88 < m˜j < 3.08 m˜j ≤ 1.88
12 2 ≤ 3 Y
12 2 4 ≤ c˜j ≤ 6 m˜j ≥ 6.15 m˜j < 6.15
12 2 7 ≤ c˜j ≤ 10 m˜j ≥ 6.15 3.75 < m˜j < 6.15 m˜j ≤ 3.75
12 3 ≤ 3 Y
12 3 4 ≤ c˜j ≤ 9 m˜j > 5.63 m˜j ≤ 5.63
12 4 0 Y
12 4 1 ≤ c˜j ≤ 8 m˜j > 7.50 m˜j ≤ 7.50
12 5,6 ≤ 7 Y
12 7 ≤ 5 Y&Eliminate
Note: nj is the number of patients at dose level j, y˜j is the number of DLTs observed by the decision time,
c˜j =
∑nj
i=1(1− δi) is the number of patients who have data pending, and m˜j is the effective number of patients
without any DLT. Dose escalation is not allowed if fewer than 2 patients at dose level j have finished the
assessment. “Y” means Yes.
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Table 2: Simulation results with sample size of 36 and cohort size of 3. The assessment window
is 3 months and the accrual rate is 2 patients per month. The MTD is in boldface.
Methods
Dose level Duration
Stop% Poor% Overdose%
1 2 3 4 5 6 (in months)
Scenario 1 Pr(tox) 0.13 0.28 0.41 0.50 0.60 0.70
R6 Sel% 43.2 30.5 7.8 0.8 0.0 0.0 35.9 17.7 70.8 10.0
Pts% 45.6 29.0 9.0 1.5 0.1 0.0
TITE-CRM Sel% 8.4 58.7 29.2 2.7 0.1 0.0 20.5 0.9 10.4 28.3
Pts% 25.2 42.6 25.1 5.7 0.7 0.0
TITE-mTPI Sel% 14.7 58.8 22.8 3.2 0.2 0.0 22.1 0.3 13.2 30.3
Pts% 29.4 46.0 20.0 3.9 0.4 0.0
TITE-keyboard Sel% 13.9 58.2 23.2 4.0 0.4 0.0 22.9 0.3 5.3 25.0
Pts% 33.3 41.9 19.3 4.5 0.7 0.1
TITE-keyboardt Sel% 14.4 58.1 23.1 3.6 0.3 0.0 22.8 0.4 4.6 17.6
Pts% 34.2 42.0 18.7 4.1 0.6 0.1
CRM Sel% 7.9 58.9 29.8 2.6 0.1 0.0 49.4 0.7 17.4 30.0
Pts% 22.9 42.1 27.2 6.4 0.8 0.1
Scenario 2 Pr(tox) 0.08 0.15 0.29 0.43 0.50 0.57
R6 Sel% 20.3 40.2 25.9 5.4 0.6 0.0 38.0 7.5 94.2 0.0
Pts% 30.3 35.6 20.6 6.1 1.0 0.1
TITE-CRM Sel% 0.2 14.1 61.7 21.9 1.9 0.1 26.6 0.2 17.1 18.2
Pts% 14.0 23.1 39.5 19.3 3.6 0.3
TITE-mTPI Sel% 1.0 21.8 56.4 17.7 2.7 0.3 26.9 0.0 26.5 12.7
Pts% 16.4 29.6 37.0 14.3 2.3 0.3
TITE-keyboard Sel% 1.1 20.8 55.5 19.9 3.3 0.4 27.2 0.0 15.4 7.5
Pts% 17.8 31.5 33.3 13.8 3.0 0.4
TITE-keyboardt Sel% 1.0 21.1 55.9 18.5 3.1 0.4 27.2 0.0 15.8 6.7
Pts% 18.1 32.1 33.2 13.5 2.7 0.4
CRM Sel% 0.1 13.1 62.8 22.4 2.1 0.1 49.8 0.0 16.2 19.4
Pts% 12.3 20.8 42.5 20.6 3.8 0.5
Scenario 3 Pr(tox) 0.28 0.42 0.49 0.61 0.76 0.87
R6 Sel% 36.2 8.8 1.1 0.0 0.0 0.0 23.3 53.9 70.8 9.9
Pts% 40.8 11.9 2.0 0.2 0.0 0.0
TITE-CRM Sel% 54.0 25.2 2.6 0.1 0.0 0.0 20.5 18.1 10.4 28.3
Pts% 56.8 25.7 6.2 1.0 0.1 0.0
TITE-mTPI Sel% 67.8 21.8 3.3 0.2 0.0 0.0 22.2 6.9 13.2 30.4
Pts% 65.0 25.7 5.1 0.5 0.0 0.0
TITE-keyboard Sel% 61.1 23.9 3.6 0.3 0.0 0.0 22.9 11.1 5.3 25.0
Pts% 61.4 25.7 6.0 1.0 0.1 0.0
TITE-keyboardt Sel% 62.4 22.7 3.3 0.3 0.0 0.0 22.8 11.4 4.6 22.9
Pts% 63.1 23.7 5.4 0.8 0.1 0.0
CRM Sel% 52.5 25.8 3.0 0.1 0.0 0.0 43.6 18.6 11.0 29.6
Pts% 54.5 24.9 7.7 1.1 0.1 0.0
Note: R6 is the rolling six design; TITE-CRM is the time-to-event CRM; TITE-keyboard and TITE-mTPI are
the proposed time-to-event versions of keyboard and mTPI designs, respectively. TITE-keyboardt is the design
that utilizes the true likelihood function (2.4). CRM is the continual reassessment method based on the complete
data. “Stop%” is the early stopping percentage; “Poor%” is the risk of poor allocation; “Overdose%” is the risk
of overdosing.
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Table 2 continued.
Methods
Dose level Duration
Stop% Poor% Overdose%
1 2 3 4 5 6 (in months)
Scenario 4 Pr(tox) 0.05 0.10 0.20 0.31 0.50 0.70
R6 Sel% 10.9 29.9 33.8 19.8 2.5 0.0 38.3 3.2 99.7 0.0
Pts% 24.0 31.2 25.6 12.6 3.6 0.4
TITE-CRM Sel% 0.0 1.5 29.5 58.9 9.9 0.1 28.3 0.1 23.7 5.7
Pts% 11.3 14.1 29.1 33.3 11.2 0.9
TITE-mTPI Sel% 0.2 5.2 35.3 49.5 9.7 0.3 28.5 0.0 38.9 3.4
Pts% 12.7 19.7 31.5 27.1 8.3 0.7
TITE-keyboard Sel% 0.2 4.3 33.2 49.8 12.0 0.4 28.8 0.0 28.1 1.7
Pts% 13.5 21.2 30.4 25.0 8.9 1.1
TITE-keyboardt Sel% 0.2 4.5 35.4 49.1 10.5 0.3 28.7 0.0 30.6 1.3
Pts% 13.7 22.1 31.1 24.3 7.9 0.9
CRM Sel% 0.1 1.4 29.7 58.9 9.9 0.1 50.0 0.0 20.7 5.5
Pts% 10.3 11.8 28.7 36.9 11.3 1.0
Scenario 5 Pr(tox) 0.06 0.08 0.12 0.18 0.30 0.41
R6 Sel% 7.6 13.6 21.9 30.7 17.1 4.8 36.4 4.4 100.0 0.0
Pts% 21.8 22.7 22.0 17.6 8.7 3.6
TITE-CRM Sel% 0.0 0.4 5.7 32.2 47.4 14.2 30.0 0.1 42.1 6.5
Pts% 11.8 12.2 17.3 25.4 23.7 9.6
TITE-mTPI Sel% 0.2 1.5 8.9 32.9 40.7 15.9 30.6 0.0 50.4 3.5
Pts% 13.2 15.5 20.1 23.9 19.2 8.2
TITE-keyboard Sel% 0.1 0.8 7.5 30.3 43.3 18.0 31.0 0.0 37.4 0.9
Pts% 13.4 15.6 19.8 23.8 18.7 8.6
TITE-keyboardt Sel% 0.1 1.3 7.9 32.5 42.0 16.2 30.8 0.0 41.3 0.9
Pts% 13.7 16.2 20.6 24.2 17.9 7.5
CRM Sel% 0.0 0.4 4.6 30.7 49.4 15.0 50.4 0.0 37.0 7.3
Pts% 10.5 9.9 15.0 27.2 26.5 10.8
Scenario 6 Pr(tox) 0.05 0.06 0.08 0.11 0.19 0.32
R6 Sel% 4.3 7.1 12.1 23.7 31.4 18.4 36.0 3.1 100.0 0.0
Pts% 19.6 19.7 19.5 18.2 12.3 8.2
TITE-CRM Sel% 0.0 0.1 2.1 10.9 38.0 48.8 32.0 0.1 49.7 0.0
Pts% 11.2 11.0 13.7 17.8 23.5 22.9
TITE-mTPI Sel% 0.1 0.5 2.6 11.2 38.0 47.7 32.6 0.0 48.9 0.0
Pts% 12.1 13.2 15.2 17.6 21.8 20.1
TITE-keyboard Sel% 0.1 0.3 1.7 9.9 38.5 49.5 32.8 0.0 45.0 0.0
Pts% 12.2 13.1 15.2 18.8 21.7 18.9
TITE-keyboardt Sel% 0.0 0.2 1.8 10.4 38.9 48.7 32.7 0.0 47.4 0.0
Pts% 12.2 13.2 15.5 19.1 21.7 18.3
CRM Sel% 0.0 0.1 1.1 8.6 40.7 49.5 50.6 0.0 42.7 0.0
Pts% 10.0 9.2 11.4 17.6 25.8 26.0
Note: R6 is the rolling six design; TITE-CRM is the time-to-event CRM; TITE-keyboard and TITE-mTPI are
the proposed time-to-event versions of keyboard and mTPI designs, respectively. TITE-keyboardt is the design
that utilizes the true likelihood function (2.4). CRM is the continual reassessment method based on the complete
data. “Stop%” is the early stopping percentage; “Poor%” is the risk of poor allocation; “Overdose%” is the risk
of overdosing.
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